Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
SS-31 (elamipretide) , a mitochondria-targeted peptide that stabilizes cardiolipin to support energy production, became the first FDA-approved mitochondrial therapeutic in 2025, though only for the rare Barth syndrome, with the brain rationale still mechanistic and no cognitive trials
Turkovic, M
After treatment with concentrations ranging from 0.0058 M to 5800 M, cell toxicity was not observed for GHK treated group (Fig
RELATED EPISODE: M&M 252: Scarring, Fibrosis, Oxidative Stress, and Psilocybin & Aging | Louise Hecker Listen or watch on your favorite platform: Support M&M: Visit the SUPPORT PAGE if you find value in this content
The gradual progression serves pharmacodynamic purposes beyond simple tolerability, allowing metabolic adaptations to develop fully
Always allow vials to come to room temperature before opening to reduce condensation, and avoid repeated freeze-thaw cycles
